Sign in / Join Now
ETFs & Funds
Justin M. Hall
) 1/20/11 10
ET: Shares oversold at $0.20 & will not stay here forever - Zybrestat has platform potential. Patience will payoff.
Add a reply...
Latest StockTalks »
people get MATN breaking news and analysis by email alert.
Get email alerts on MATN »
Mateon Therapeutics, Inc.
Get latest price
From other sites
Mateon Provides Corporate Update And Reports Second Quarter 2016 Financial Results
at TheStreet (Aug 3, 2016)
OXiGENE Gets Orphan Drug Status For Its CA4P To Treat Glioma
at Benzinga (Jun 10, 2016)
OXiGENE to Present at the 14th Annual BIO Investor Forum
at 4-traders.com (Oct 16, 2015)
OXIGENE : Other Events, Financial Statements and Exhibits (form 8-K)
at 4-traders.com (Oct 8, 2015)
OXiGENE (OXGN) to Initiate Two Phase II/III Studies on CA4P
at Zacks.com (Sep 30, 2015)